Accropeutics’ TYK2/JAK1 Inhibitor AC-201 Achieves Key Endpoints in Phase II Psoriasis Trial

Accropeutics announced that its oral TYK2/JAK1 inhibitor, AC-201, successfully met the primary and key secondary endpoints in a Phase II trial for moderate to severe plaque psoriasis. The study included 145 patients across multiple sites in China and tested three doses: 25mg twice daily, 50mg twice daily, and 100mg once daily versus placebo.

After 12 weeks, the primary endpoint PASI-75 response rates were 31.4% (25mg), 74.3% (50mg), and 59.5% (100mg), compared to 8.1% for placebo. The secondary endpoint PASI-90 also showed improvements, with 20%, 48.6%, and 24.3% response rates for the respective doses versus 2.7% for placebo. The static Physician’s Global Assessment (sPGA 0/1) results supported these findings.

Accropeutics stated that the positive efficacy and safety data support moving AC-201 into Phase III trials.

27-05-2025